subcutaneous desferrioxamine daily infusion on iron balance in 23 thalassemia major children, aged 8-74 months, with transfusional iron accumulation less than 3.8 g at the outset of the trial.
The Insignis Syringe Infusion System is a robust ... These additional subcutaneous therapies include deferoxamine, factor, anti-nausea drugs, and monoclonal antibodies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback